Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

6.090 +0.080 (+1.33%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	158,013
Open	6.040
Bid (Size)	6.090 (200)
Ask (Size)	6.120 (100)
Prev. Close	6.010
Today's Range	5.810 - 6.120
52wk Range	4.650 - 8.290
Shares Outstanding	9,947,915
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Today 8:00 EST

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

November 04, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Performance

YTD	+6.7%	+6.7%
1 Month	+0.5%	+0.5%
3 Month	-1.8%	-1.8%
6 Month	+7.0%	+7.0%
1 Year	-16.0%	-16.0%

More News

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

October 27, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Get insights into the top gainers and losers of Friday's pre-market session. ↗

October 24, 2025

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 24, 2025

Via Benzinga

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

October 24, 2025

From Coya Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 23, 2025

Via Benzinga

Coya Therapeutics Announces Proposed Public Offering of Common Stock

October 23, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

October 07, 2025

From Coya Therapeutics, Inc.

Via Business Wire

EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease ↗

September 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 25, 2025

Via Benzinga

What's Going On With Coya Therapeutics Stock? ↗

August 25, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 25, 2025

Via Benzinga

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease

July 24, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

July 22, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Updated Lineup Announced for iAccess Alpha's Virtual Summer Investment Conference, June 24–25, 2025

June 23, 2025

Via ACCESS Newswire

iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025

June 18, 2025

Via ACCESS Newswire

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

June 18, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

June 02, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 16, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 13, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 08, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗

May 01, 2025

Via Benzinga

Coya Therapeutics Announce Positive Interim Result from Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

April 24, 2025

Via Get News

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

April 24, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Coya Therapeutics, Inc. - Common Stock publicly traded?

Yes, Coya Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Coya Therapeutics, Inc. - Common Stock trade on?

Coya Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Coya Therapeutics, Inc. - Common Stock?

The ticker symbol for Coya Therapeutics, Inc. - Common Stock is COYA on the Nasdaq Stock Market

What is the current price of Coya Therapeutics, Inc. - Common Stock?

The current price of Coya Therapeutics, Inc. - Common Stock is 6.090

When was Coya Therapeutics, Inc. - Common Stock last traded?

The last trade of Coya Therapeutics, Inc. - Common Stock was at 11/12/25 04:00 PM ET

What is the market capitalization of Coya Therapeutics, Inc. - Common Stock?

The market capitalization of Coya Therapeutics, Inc. - Common Stock is 60.58M

How many shares of Coya Therapeutics, Inc. - Common Stock are outstanding?

Coya Therapeutics, Inc. - Common Stock has 61M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.